Rohit Chandwani, MD, PhD

Associate Professor of Surgery

Leader, Cancer Therapeutics (Sandra and Edward Meyer Cancer Center)

Contact & profiles

Appointments

Associate Professor of SurgeryPrimary
Surgery · 2025–
Associate Professor of Cell and Developmental Biology
Cell and Developmental Biology · 2025–
Frank Glenn Faculty Scholar in Surgery
Surgery · 2024–
Mildred L. and John F. Rasweiler Research Scholar Award in Cancer Research
Surgery · 2021–
Associate Professor
Weill Cornell Graduate School — Molecular Biology · 2018–
Physician
NewYork-Presbyterian Hospital

Past Appointments

Assistant Professor of Cell and Developmental Biology
Cell and Developmental Biology · 2018–2025
Assistant Professor of Surgery
Surgery · 2017–2025
Fellow in Surgery
Surgery · 2014–2016

Centers

Education

Highlights

1
Developmental cell · 2026
WSWhitney SissoPZPaul ZumboWFWilliam FallKFKatherine Ferrick+4 more →RCRohit Chandwani
PMID: 42480541PMCID: PMC13404274DOISenior author1 citations
2
Cancer cell · 2024
JPJiwoon ParkYMYinuo MengWSWhitney SissoWFWilliam Fall+9 more →RCRohit Chandwani
PMID: 39214094PMCID: PMC11419252DOISenior author87 citations
3
Developmental cell · 2023
WFWilliam FallYMYinuo MengOEOlivier Elemento EPErika Patel+1 more →RCRohit Chandwani
PMID: 38056453PMCID: PMC10843773DOISenior author50 citations

5 grants

MPI
Defining the oncogenic potential and therapeutic dependencies of PDAC-associated KRAS variants
National Cancer Institute · 2024–2029
R01CA290616-02
PI
Defining the molecular determinants of inflammatory memory in the pancreas
National Institute of Diabetes and Digestive and Kidney Diseases · 2024–2029
R01DK138154-03
PI
Defining Rac1-mediated bypass of senescence as a molecular vulnerability in pancreatic cancer
American Cancer Society · 2025–2028
RSG-24-1325001-01-MM
Sub-PI
Networks for functional regulation of pancreatic acinar-ductal metaplasia and epithelial plasticity
National Institute of Diabetes and Digestive and Kidney Diseases · 2022–2027 · via Columbia University
R01DK060694-23
KP
Meng | PhRMA Foundation Predoctoral Fellowship 2026
PhRMA Foundation · 2026–2026Fellowship
PHRMA 254134-01

Completed grants (10)

KP
Inflammation-induced cellular plasticity in pancreatic homeostasis and tumorigenesis
National Cancer Institute · 2021–2023Fellowship
F31CA265166-01
PI
Hnf1b defines an epigenetic ontology of human pancreatic cancer
Pancreatic Cancer Action Network, Inc. · 2021–2023
21-20-CHAN
PI
Leveraging Rac1 dependency to drive therapeutic strategies in human pancreatic cancer
Sanofi S.A. · 2022–2023BioPharma Alliance
BP 225089-01
PI
Memory of Inflammation in the Pre-Neoplastic Pancreas
American Surgical Association Foundation · 2019–2022
ASAF 191645-02
PI
The epigenetic plasticity of pancreatic ductal adenocarcinoma
American Association for Cancer Research · 2018–2022
AACR 180731-01
Sub-PI
Comprehensive genetic dissection of druggable Kras targets
National Cancer Institute · 2018–2022 · via Dartmouth College
R01CA204228-03
KP
Mutant Kras allele-specific epigenetic plasticity in PDAC initiation
Prevent Cancer Foundation · 2020–2022
PCF 194611-01
PI
A Genetic Model for Ampullary Cancer Subtypes
Memorial Sloan Kettering Cancer Center · 2020–2021Contract
No publications yet
MSKCC 212098-01
PI
Mitochondrial control of epigenetic reprogramming in pancreatic tumorigenesis
National Cancer Institute · 2019–2021
R21CA244025-02
PI
The epigenetic plasticity of pancreatic ductal adenocarcinoma
American Association for Cancer Research · 2017–2018
16-70-25-CHAN

Completed & closed trials (1)

PI
Molecular, metabolic, and epigenetic determinants of pancreatic and liver cancer
Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2023)

Two Weill Cornell Medicine Faculty Members Elected to ASCI
February 13, 2025
Two Weill Cornell Medicine physician-scientists, Dr. Niroshana Anandasabapathy and Dr. Rohit Chandwani, have been elected members of the American Society for Clinical Investigation (ASCI) for 2025.
Researchers Develop Insights into KRAS Mutations in Pancreatic Cancers
October 2, 2024
A common mutation in the KRAS gene is associated with improved overall survival in pancreatic ductal adenocarcinoma (PDAC) compared with other variants, in part because the mutation appears to lead to less invasiveness and weaker biological activity, according to a multicenter study conducted at Weill Cornell Medicine, Memorial Sloan Kettering, and other institutions.